Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

New drug combination boosts breast cancer survival

  • Comment
Adding the drug Epirubicin to post-operative chemotherapy regimens for early stage breast cancer can significantly reduce the risk of a women dying from the disease, according to a new UK wide study.

Adding the drug Epirubicin to post-operative chemotherapy regimens for early stage breast cancer can significantly reduce the risk of a women dying from the disease, according to a new UK widestudy.

The results come from two major trials (NEAT and BR 9601) including 2,400 women at 75 treatment centresacross across the countrythat are published today.

Findings show thatadding Epirubicin to the established chemotherapy regimen CMF - cyclophosphamide, methotrexate and fluorouracil-can cut the risk of death from the disease by more than 30% compared with using CMF alone.

The results remained significant at two and four years follow up and there were no long-term adverse impact on quality of life, the authors add.

Lead author Chris Poole from the University of Birmingham said: 'The size of treatment benefit seen in these trials is dramatic and surpassed all expectations. Although some cancer centres are using Epirubicin-CMF routinely, it is still not standard across the country.'

The New England Journal of Medicine (2006)




  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.